Want the news summarized?
Subscribe to The Morning Report.
Maybe all is not lost in world of life science venture capital. In what amounts to a rare piece of good news for the beleaguered industry, Domain Associates announced Monday that it is establishing a $500 million fund that will be devoted to exclusively to life sciences.
The announcement from Domain, which is based both in San Diego and Princeton, N.J., comes at a time of unprecedented retrenchment for the industry both here and elsewhere. Among Domain’s success stories are San Diego-based companies NuVasive and Orexigen Therapeutics. The former is a medical device company specializing in spinal implants, and the latter is working on an obesity drug.
Here is a statement from Domain’s announcement:
Domain will continue to focus on early stage companies in the drug and device sectors with a meaningful portion of its efforts going towards the diagnostics and instrumentation sectors.
A hat tip goes to Xconomy, for alerting me to this item.